➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Johnson and Johnson

Last Updated: October 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,227,484

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,227,484 protect, and when does it expire?

Patent 8,227,484 protects NUEDEXTA and is included in one NDA.

This patent has seventy-two patent family members in twenty-one countries.

Summary for Patent: 8,227,484
Title:Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Abstract: Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
Inventor(s): Yakatan; Gerald (Del Mar, CA), Berg; James (San Diego, CA), Pope; Laura (Carlsbad, CA), Smith; Richard Alan (La Jolla, CA)
Assignee: Avanir Pharmaceuticals, Inc. (Aliso Viejo, CA)
Application Number:13/415,067
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,227,484
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,227,484

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Avanir Pharms NUEDEXTA dextromethorphan hydrobromide; quinidine sulfate CAPSULE;ORAL 021879-001 Oct 29, 2010 AB RX Yes Yes   Start Trial   Start Trial TREATMENT OF PSEUDOBULBAR AFFECT   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,227,484

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 399553   Start Trial
Australia 2003251971   Start Trial
Australia 2008201775   Start Trial
Australia 2010212348   Start Trial
Australia 2013202184   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.